THE DEAL, AT A GLANCE
From the announcementGuardant Health
01What it doesGuardant Health Expands Cancer Testing Platform With MetaSight Deal And Shield Growth This addresses liquid Biopsy Market is Expected to Witness Robust Growth by 2032,…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02Who is involvedBacked by VariousFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedGuardant Health raised $250M Growth RoundFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersGuardant Health’s deal thesis is that blood-based colorectal cancer detection can address the gap where half of people who need colonoscopies do not get them.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Guardant Health · Financing Record
Explore source-linked visual explanations for Guardant Health. Unsupported claims are withheld while source review continues.
Record 461 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →